Search Results for: "lecanemab"

The Institute for Clinical and Economic Review (ICER) conducted a systematic literature review and cost-effectiveness analysis to evaluatethe health and economic outcomes of lecanemab for early AD. We present the summary of our findings and highlights of the policy discussion with key stakeholders held at a public meeting of the California Technology Assessment Forum (CTAF) […]

Independent appraisal committee voted that currently available evidence is not adequate to demonstrate a net health benefit for lecanemab when compared to supportive care.

Currently available evidence is rated as promising but inconclusive to determine whether lecanemab provides a net health benefit over supportive care; the evidence suggests drug would achieve common thresholds for cost-effectiveness if priced between $8,900 - $21,500 per year.

Independent panel members debate the evidence on the effectiveness and value of new drugs and other health care interventions at ICER public meetings; nominations requested by December 13.

We are honored to announce that ICER’s President, Steve Pearson, MD, MSc is among those leaders selected for STAT's 2023 STATUS List.

Public comment period now open until February 2, 2023; Requests to make oral comment during public meeting also being accepted

Report will be subject of CTAF meeting in July 2022; Draft Scoping Document open to public comment until January 19, 2022.

Interventions of Interest: The independent appraisal committee voted that currently available evidence is not adequate to demonstrate a net health benefit for lecanemab when compared to supportive care. Using best estimates from current data, ICER analyses suggest lecanemab would achieve common thresholds for cost-effectiveness if priced between $8,900 – $21,500 per year. Final Documents ICER’s […]

What Is In The Final Evidence Report? The full report includes a summary of the public meeting discussion, and any necessary updates to ICER’s conclusions following those discussions. When Is The Final Evidence Report Released? Around three weeks after the public meeting. What is the ICER Snapshot? The Snapshot is a patient-friendly summary of ICER’s […]

ICER’s Collaboration with the Department of Veterans Affairs In 2017, the Department of Veterans Affairs began integrating ICER’s research into its pricing negotiations to provide greater value to Veterans and taxpayers. At the time, there was some consternation from industry, with the National Pharmaceutical Council asking whether the partnership could simply be “…a means to […]